Patent application number | Description | Published |
20090104215 | Methods and compositions for modulating tumor cell activity - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin. | 04-23-2009 |
20100120147 | ANTAGONIST OF LIGANDS AND USES THEREOF - The invention provides multivalent ligand binging agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, said agent comprising the general structure I: (-linker1) | 05-13-2010 |
20110033471 | METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding the clusterin. | 02-10-2011 |
20110236309 | ANTAGONISTS OF LIGANDS AND USES THEREOF - The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-β superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-β superfamily, said agent comprising the general structure (I): (-linker1) | 09-29-2011 |
20120040863 | PROCESS FOR TUMOUR CHARACTERISTIC AND MARKER SET IDENTIFICATION, TUMOUR CLASSIFICATION AND MARKER SETS FOR CANCER - A process to identify tumour characteristics involves obtaining three different marker sets each predictive of a characteristic of interest, obtaining a sample gene expression signals from tumour cells, adding a reporter to affect a change in the sample permitting assessment of a gene expression signal of interest in the tumour, combining the gene expression signals with the reporter, correlating the extracted gene expression signals to the three different marker sets, assigning a designation to the extracted gene expression signals according to the following rankings: if the correlation of all three predictive gene expression signal sets predict it to have characteristics of concern, it is designated a bad tumour; if the correlation of all three predictive gene expression signal sets predict it to lack characteristics of concern it is designated a good tumour; and, if the correlation of all three predictive gene expression signal sets do not provide the same predicted clinical outcome, the tumour is designated as “intermediate”; and, outputting said designation. | 02-16-2012 |
20120071635 | METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding the clusterin. | 03-22-2012 |
20120121507 | PEPTIDE LIGANDS FOR CLUSTERIN AND USES THEREOF - Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated. | 05-17-2012 |
20130089499 | ANTAGONISTS OF LIGANDS AND USES THEREOF - The invention provides multivalent ligand binding agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, the agent having the general structure I: | 04-11-2013 |
20130089500 | ANTAGONISTS OF LIGANDS AND USES THEREOF - The invention provides multivalent ligand binding agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, the agent having the general structure I: | 04-11-2013 |
20130251712 | COVALENTLY DIMERIZED BIVALENT BINDING AGENTS - The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind. The invention is particularly useful for covalently dimerized receptor-based ligand traps where the binding domains are receptor ligand-binding domains, such as those of TGF-β receptors. | 09-26-2013 |
20130266564 | ANTIBODIES SELECTIVE FOR CELLS PRESENTING ErbB2 AT HIGH DENSITY - An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY | 10-10-2013 |
20130295086 | ANTIBODIES SELECTIVE FOR CELLS PRESENTING EGFR AT HIGH DENSITY - Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells. | 11-07-2013 |